{"id":20541,"date":"2023-10-17T10:07:57","date_gmt":"2023-10-17T08:07:57","guid":{"rendered":"https:\/\/ggba.swiss\/?p=20541"},"modified":"2023-10-17T10:07:58","modified_gmt":"2023-10-17T08:07:58","slug":"mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/","title":{"rendered":"Mimix Biotherapeutics\u2019 breakthrough tissue regeneration treatment receives strategic investment"},"content":{"rendered":"\n

Located in Biel (canton of Bern), Mimix Biotherapeutics<\/a> has invested over a decade in research and development. Their core product, FastSkin, is indicative of the future potential of personalized medicine. While FastSkin remains a focal point, the company’s interests span a wide range of areas, including regenerative medicine, drug development, and cellular agriculture.<\/p>\n\n\n\n

At the heart of Mimix\u2019s innovations is the Sound Induced Morphogenesis technology (SIM<\/a>). This process employs acoustic waves to structure biological materials, such as cells or tissues, into precise three-dimensional constructs. Emulating nature\u2019s intricate design strategies, it offers a novel approach to biomedical applications.<\/p>\n\n\n\n

The funding round saw contributions from established investor Heraeus Group<\/a> and newcomer Asia Jetway Pte. The latter, headquartered in Singapore, is known for its extensive portfolio in healthcare solutions across Southeast Asia, comprising affiliate companies such as LandMover, Shanghai Keyman, and others.<\/p>\n\n\n\n

Innovating in the sphere of chronic wound management<\/h4>\n\n\n\n

The shared vision of these investors aligns with Mimix\u2019s goal of advancing wound treatment methodologies. FastSkin is positioned as a treatment that could potentially optimize patient care and bring about efficiencies in healthcare expenditure.<\/p>\n\n\n\n

Marc Thurner, the CEO of Mimix, stated, “We are thrilled to have the support of Heraeus Group and Asia Jetway, as we work to bring our innovative wound treatment to market. Their expertise and resources will be invaluable to accelerate go-to-market and internationalization plans.\u201d<\/p>\n\n\n\n

Given the conclusion of this financial milestone, Mimix is a step closer to realizing its mission of innovating in the sphere of chronic wound management. As part of its future roadmap, Mimix is actively seeking collaborations and partnerships across both industry and academia, aiming to further leverage its proprietary technologies in the broader biomedical landscape.<\/p>\n","protected":false},"excerpt":{"rendered":"

Biel-based Mimix Biotherapeutics announced the closure of a significant investment round, drawing participation from both European and Asian investors. This capital infusion is earmarked for the clinical development of FastSkin, a new method aimed at both chronic and acute wound management.<\/p>\n","protected":false},"author":6,"featured_media":20542,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[912,894,926,902],"class_list":["post-20541","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-biotech","tag-financing","tag-medtech","tag-personalized-medicine"],"acf":[],"yoast_head":"\nStrategic investment for Mimix's tissue regeneration treatment<\/title>\n<meta name=\"description\" content=\"Mimix Biotherapeutics announced the closure of a significant investment round with the participation of European and Asian investors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Strategic investment for Mimix's tissue regeneration treatment\" \/>\n<meta property=\"og:description\" content=\"Mimix Biotherapeutics announced the closure of a significant investment round with the participation of European and Asian investors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-17T08:07:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-17T08:07:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Mimix-Fast-Skin-1180x811-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Mimix Biotherapeutics\u2019 breakthrough tissue regeneration treatment receives strategic investment\",\"datePublished\":\"2023-10-17T08:07:57+00:00\",\"dateModified\":\"2023-10-17T08:07:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/\"},\"wordCount\":293,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Mimix-Fast-Skin-1180x811-1.jpg\",\"keywords\":[\"Biotech\",\"Financing\",\"Medtech\",\"Personalized Medicine\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/\",\"url\":\"https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/\",\"name\":\"Strategic investment for Mimix's tissue regeneration treatment\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Mimix-Fast-Skin-1180x811-1.jpg\",\"datePublished\":\"2023-10-17T08:07:57+00:00\",\"dateModified\":\"2023-10-17T08:07:58+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Mimix Biotherapeutics announced the closure of a significant investment round with the participation of European and Asian investors.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Mimix-Fast-Skin-1180x811-1.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Mimix-Fast-Skin-1180x811-1.jpg\",\"width\":1180,\"height\":811,\"caption\":\"Mimix\u2019s objective, as outlined in its strategic vision, is to introduce this wound care product to the US market by the second half of 2024. | \u00a9 Mimix Biotherapeutics\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mimix Biotherapeutics\u2019 breakthrough tissue regeneration treatment receives strategic investment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Strategic investment for Mimix's tissue regeneration treatment","description":"Mimix Biotherapeutics announced the closure of a significant investment round with the participation of European and Asian investors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/","og_locale":"en_US","og_type":"article","og_title":"Strategic investment for Mimix's tissue regeneration treatment","og_description":"Mimix Biotherapeutics announced the closure of a significant investment round with the participation of European and Asian investors.","og_url":"https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2023-10-17T08:07:57+00:00","article_modified_time":"2023-10-17T08:07:58+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Mimix-Fast-Skin-1180x811-1.jpg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Mimix Biotherapeutics\u2019 breakthrough tissue regeneration treatment receives strategic investment","datePublished":"2023-10-17T08:07:57+00:00","dateModified":"2023-10-17T08:07:58+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/"},"wordCount":293,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Mimix-Fast-Skin-1180x811-1.jpg","keywords":["Biotech","Financing","Medtech","Personalized Medicine"],"articleSection":["Life sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/","url":"https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/","name":"Strategic investment for Mimix's tissue regeneration treatment","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Mimix-Fast-Skin-1180x811-1.jpg","datePublished":"2023-10-17T08:07:57+00:00","dateModified":"2023-10-17T08:07:58+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Mimix Biotherapeutics announced the closure of a significant investment round with the participation of European and Asian investors.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Mimix-Fast-Skin-1180x811-1.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Mimix-Fast-Skin-1180x811-1.jpg","width":1180,"height":811,"caption":"Mimix\u2019s objective, as outlined in its strategic vision, is to introduce this wound care product to the US market by the second half of 2024. | \u00a9 Mimix Biotherapeutics"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"Mimix Biotherapeutics\u2019 breakthrough tissue regeneration treatment receives strategic investment"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/20541","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=20541"}],"version-history":[{"count":2,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/20541\/revisions"}],"predecessor-version":[{"id":20546,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/20541\/revisions\/20546"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/20542"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=20541"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=20541"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=20541"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}